COMMUNIQUÉS West-GlobeNewswire

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
14/09/2024
- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + [...]
Company Statement on FDA Advisory Committee Meeting
14/09/2024
MORRISTOWN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- The Gastrointestinal Drugs Advisory Committee (GIDAC) of the U.S. Food and Drug Administration (FDA) met today to discuss Intercept’s supplemental New Drug [...]
Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.
14/09/2024
MARKHAM, Ontario, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Dr. Pardeep Nijhawan (“ Dr. Nijhawan ”) announces that as a result of grants of restricted share units (“ RSUs ”) of Edesa Biotech, Inc. (“ Edesa ”), when combined [...]
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
13/09/2024
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the “Determination Letter”) [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13/09/2024
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
KKR to Purchase of 11,619,998 Shares of BrightSpring Health Services Common Stock from Walgreens Boots Alliance
13/09/2024
LOUISVILLE, Ky., Sept. 13, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, [...]
Fagron completes share buy-back program
13/09/2024
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 13 September 2024 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program today. In the last [...]
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
13/09/2024
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNP Current treatment options leave many patients with uncontrolled disease and often result in the [...]
Virbac : Rapport financier semestriel 2024
13/09/2024
Ci-joint le rapport financier semestriel 2024 de Virbac Pièce jointe Rapport financier semestriel_2024 pour publication
Virbac : Half-yearly financial report 2024
13/09/2024
Please find attached 2024 Half-yearly financial report of Virbac Attachment Half-Yearly Financial Report_2024 for publication
Virbac : Public release of the Half-Year Financial Report at 30 June 2024.
13/09/2024
Public release of the Half-Year Financial Report at 30 June 2024. The Group released and filed its 2024 half-year financial report with the French “Autorité des marchés financiers”. The document is also available on the [...]
Virbac : Communiqué de mise à disposition du rapport financier semestriel au 30 juin 2024.
13/09/2024
Communiqué de mise à disposition du rapport financier semestriel au 30 juin 2024. Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son rapport financier [...]
Le traitement prophylactique par dexaméthasone réduit les réactions liées à la perfusion chez les patients atteints d'un cancer du poumon non à petites cellules avancé muté EGFR et traités par RYBREVANT® ▼ (amivantamab) par voie intraveineu
13/09/2024
La prémédication à une dose de 8 mg à entraîné un taux de réaction lié à la perfusion de 22,5 pour cent avec l'amivantamab par voie intraveineuse, soit trois fois moins que le taux de 67,4 pour cent historiquement [...]
BioNexus Gene Lab Corp. Signs Strategic Outsourcing Agreement with VITARRAY Global Pte. Ltd.
13/09/2024
KUALA LUMPUR, Malaysia, Sept. 14, 2024 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce that [...]
Virbac : the board of directors announces a capital reduction through cancellation of treasury shares
13/09/2024
During the meeting held on September 13, 2024, the board of directors, acting on the authorization granted by the combined shareholders’ meeting on June 20, 2023, decided to reduce the share capital of Virbac by [...]
Virbac : le conseil d’administration annonce une réduction de capital par voie d’annulation d’actions propres
13/09/2024
Le conseil d’administration réuni le 13 septembre 2024 a, sur autorisation de l’assemblée générale mixte du 20 juin 2023, décidé de réduire le capital social de Virbac par voie d’annulation de 67 340 actions propres. [...]
Virbac: Information on the departure of Sébastien Huron
13/09/2024
At its meeting on September 13, 2024, the board of directors acknowledged the resignation of Sébastien Huron, effective as of September 27, 2024, from his positions as chief executive officer of Virbac and director of [...]
Virbac: Informations sur les conditions de départ de Sébastien Huron
13/09/2024
Lors de sa réunion du 13 septembre 2024, le conseil d’administration a constaté la démission de Sébastien Huron, avec effet au 27 septembre 2024, de son mandat de directeur général de Virbac et d'administrateur de [...]
Virbac 2024 half-year results
13/09/2024
Exceptional business momentum in the first half, with revenue up 16.1% at constant exchange rates Strong growth in adjusted current operating income 1 +3.4 points compared with 2023 to reach a record level at 21.4% of [...]

Pages